MEDICAL BREAKTHROUGH: Israeli Hospital Implants Revolutionary Brain Pacemaker to Treat Epilepsy Without Opening Skull
In a significant medical first, doctors at Beilinson Hospital in Petach Tikvah have successfully implanted an innovative brain stimulation device in a 42-year-old woman suffering from epilepsy, using a new technique that allows electrical treatment of the brain without opening the skull or inserting electrodes directly into brain tissue.
The groundbreaking procedure, performed at the Clalit-operated hospital, marks the first use of the technology in Israel and the first implantation of its kind outside Europe. The device, known as EASEE, offers a potentially important treatment option for patients whose epileptic seizures cannot be adequately controlled with medication and who may not be suitable candidates for conventional brain surgery.
Unlike traditional surgical approaches to brain stimulation, which may require electrodes to be inserted into the brain, the EASEE system is positioned beneath the patient’s scalp but above the skull bone. From that location, it delivers carefully controlled electrical stimulation intended to reduce abnormal brain activity responsible for triggering seizures.
The first Israeli recipient of the device is Olga Moisa, 42, who has struggled with epilepsy for approximately 15 years after suffering a stroke.
Her condition had continued to affect her life despite years of treatment, prompting physicians to consider the newly available technology as another possible means of controlling her seizures.
The implantation was carried out on August 31, with physicians positioning the stimulation components over the region of the brain associated with her seizures. The system is connected to a battery-powered pulse generator implanted beneath the skin in the chest, which supplies the electrical impulses used in treatment.
Because the electrodes remain outside the skull, the procedure avoids the need to penetrate the brain itself, an important distinction from more invasive forms of neurostimulation.
In the days following the operation, Moisa’s family reported an encouraging early development: she had not experienced any epileptic seizures since the implantation.
Her son shared the news of the apparent improvement, although the medical team emphasized that the observation period was still far too short to establish whether the treatment would provide lasting seizure control.
The German-developed technology is intended primarily for patients with drug-resistant focal epilepsy, a form of the neurological disorder in which seizures originate in a particular region of the brain. Approximately one-third of people with epilepsy do not achieve adequate seizure control through medication alone, leaving many patients facing years of recurring attacks despite continued medical treatment.
For such patients, conventional treatment options can include surgery to remove the affected brain tissue or implanting electrodes within the skull to deliver electrical stimulation. However, these procedures are not appropriate for everyone, particularly when the location of the seizure-producing region makes surgery difficult or potentially dangerous.
The EASEE device, developed by German medical technology company Precisis, was designed to provide a less invasive alternative. Its name stands for Epicranial Application of Stimulation Electrodes for Epilepsy.
The system uses a thin electrode array positioned directly above the area where seizures originate. Although the electrodes do not touch the brain, the electrical impulses they deliver can influence the underlying neural activity, with the aim of reducing the frequency and severity of seizures.
The procedure generally takes approximately 60 to 90 minutes, and patients can often return home within a day or two. The device is typically activated several weeks after implantation, with specialists subsequently adjusting its settings according to the patient’s condition and response to treatment.
The technology has already undergone clinical testing in Europe, producing encouraging results among patients whose epilepsy had resisted conventional medication.
A study published in the medical journal JAMA Neurology examined 33 patients who received the device at specialized epilepsy centers in Germany and Belgium. Among the 32 patients evaluated after six months of stimulation, approximately 53% experienced a reduction of at least 50% in their seizure frequency. The median reduction in seizures across the group was 52%.
Researchers reported no serious adverse events attributed to the device or implantation procedure during the initial study period.
Additional findings published in the journal Epilepsia in 2025 provided evidence of longer-term benefits. Among 26 patients who continued treatment and supplied seizure records through the two-year follow-up, approximately 65% experienced a reduction of at least 50% in seizure frequency, while the median reduction reached 68%.
The researchers also reported improvements in patients’ health-related quality of life, without serious complications attributed to the implantation or stimulation during the follow-up period.
Nevertheless, the studies involved relatively small groups of patients and were conducted without randomized control groups, meaning additional research is necessary to establish the treatment’s effectiveness across a broader population.
The EASEE system received European regulatory certification in 2022 and has since been introduced at epilepsy treatment centers in several European countries, including Germany, Austria, Switzerland, Portugal, and the United Kingdom.
In August 2026, a British hospital reported its first implantation of the device in a 60-year-old woman who had experienced epilepsy since early childhood. The procedure was part of the technology’s expanding use within Britain’s National Health Service.
The technology is also moving toward clinical evaluation in the United States. In November 2025, Precisis announced that the U.S. Food and Drug Administration had authorized a pivotal clinical study to assess the system’s safety and effectiveness in American patients. The planned study is expected to enroll approximately 200 participants.
The introduction of the device at Beilinson represents another step in making the treatment available beyond the European medical centers where it was initially developed and tested.
For Moisa, the significance of the procedure is particularly personal. After approximately 15 years of living with epilepsy following her stroke, she now has access to a treatment designed to address the neurological activity responsible for her seizures without requiring surgery inside the skull.
Doctors will continue monitoring her condition to determine whether the initial encouraging results develop into sustained improvement. Because the treatment generally requires a period of activation, adjustment, and follow-up, the absence of seizures immediately after surgery cannot by itself establish that the device has successfully controlled her epilepsy.
The medical team hopes that, as experience with the technology grows, the procedure will become an additional option for other patients who have exhausted conventional treatments.
For now, the successful implantation at Beilinson marks an important expansion of epilepsy treatment in Israel, bringing a relatively new form of brain stimulation to patients who previously faced a much narrower range of medical options.
{Matzav.com}
